diabetestalk.net

Animas Insulin Pump Supplies

Animas® Vibe™ Insulin Pump Receives Fda Approval For Adults With Type Ii Diabetes

Animas® Vibe™ Insulin Pump Receives Fda Approval For Adults With Type Ii Diabetes

Integrated System Streamlines Diabetes Management for Diabetics Los Angeles, California, March 25, 2015 – Diabetic supplies company Mini Pharmacy announces the addition of the Animas Vibe insulin pump and Continuous Glucose Monitoring (CGM) system for the management of insulin in diabetic adults ages 18 and older. The Animas pump is the first and only integrated system to feature Dexcom G4® PLATINUM sensing technology with proven accuracy. Animas’s insulin pump allows patients to view glucose data and if desired, to administer insulin directly from the pump. This simplifies and aids diabetics in making better decisions fine-tuning insulin delivery and managing their diabetes. “We are excited to add the Animas Vibe insulin pump to our extensive product line. Animas expands our insulin pump portfolio and delivers on our promise to provide a range of solutions that help our customers,” said Richard Fox, President of Mini Pharmacy. The Animas Vibe system, via the pump screen, provides patients with their latest glucose readings and a complete view of glucose rates of change over time. Their CGM technology measures glucose levels every five minutes and provides real-time glucose values, as well as vital trend information. Continuous Glucose Monitoring has been shown to improve glycemic control in patients 25 years and older through lower HbA1c levels and fewer bouts of hypoglycemia. Users may personalize dosing with individual insulin-to-carb ratios, insulin sensitivity factors, and blood glucose targets in 30-minute increments with up to 12 personal settings. “For many people who are insulin dependent, diabetes is a demanding disease that can require day-to-day and hour-by-hour management. We are pleased to now offer people with diabetes in the U.S. a solution wi Continue reading >>

Animas Pumps Discontinued

Animas Pumps Discontinued

WRITTEN BY: Michelle Boise Editor’s Note: This announcement affects customers in the US and Canadian markets only. CHESTERBROOK, Pa., – Johnson & Johnson’s Diabetes Care Company, Animas Corporation has announced the intended discontinuation of manufacturing The Animas® Vibe® and OneTouch Ping® insulin pumps. Animas Corporation has pledged to continue customer support and training, as well as provide warranty for the pump supplies associated with the discontinued devices for a period of time. Through Sept. 30, 2019, Medtronic will provide Animas supplies to those who continue using these insulin pumps. Animas Corporation has pledged to continue customer support and training, as well as provide warranty for the pump supplies associated with the discontinued devices for a period of time. Currently, only US and Canadian customers are affected. Details still to be released regarding how this will impact those in Australia, New Zealand and international markets. Valerie Asbury, General Manager of Animas Corporation, made a statement to current pump users, saying, “We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure them that we will be with them every step of the way throughout this transition.” While current Animas users will have support to transition to Medtronic at no cost (avoiding the threat of losing a pump altogether or fighting with insurance providers for coverage), the move leaves many in the US and Canadian diabetes community uneasy. Just earlier this year, Roche discontinued its Accu-Chek® insulin pump, leaving one less device option for people with Type 1 diabetes in an already small pump market. Roche also directed customers to Medtronic. For many with Type 1 who depend on insulin Continue reading >>

Animas Shuts Down Its Pump Line

Animas Shuts Down Its Pump Line

Johnson & Johnson has decided to disconnect from the insulin pump market, a move that will leave Animas, Animas Vibe, and OneTouch Ping users looking for a new pump. A press release by the company said it has partnered with Medtronic to transition its existing customers to Medtronic’s pump line. Johnson & Johnson representatives cited increased competition as the reason the Animas brand has being discontinued. This news was first reported in the diabetes news sphere by Diabetes Mine on its Facebook page. sponsor The move to pull the plug on the Animas pump brand has long been seen as a possibility by market watchers, but outwardly Johnson & Johnson has professed a “business as usual” attitude with customers. When Diabetic Investor blogger David Kliff wrote about the possibility of consolidation in the insulin pump market in a February 2017 Diabetic Connect article, the company responded to the article by saying, “Animas continues to manufacture, deliver and support its products and provide the service our patients expect. We remain committed to our patients, and we intend to honor our warranty and do not anticipate any interruptions to patients’ pump therapy. If patients or potential patients have any concerns, they can contact Animas online or at 1-877-YES-PUMP.” That number’s phone tree now prompts customers to learn more about the decision to shudder the Animas pump line. I called the number and was connected with a call center operator who read a prepared statement about the transition. It said that customers whose warranties expire on or after September 30th, 2019 will have the option to transition to a Medtronic 630G free of charge; this Medtronic pump automatically suspends insulin delivery should the system’s CGM detect that blood glucose levels Continue reading >>

Medtronic Service And Support For Animas Insulin Pump Customers

Medtronic Service And Support For Animas Insulin Pump Customers

As you may have read, this morning Animas announced its decision to close its insulin pump business, discontinuing the manufacturing and sale of all Animas® Vibe® and OneTouch Ping® insulin pumps in the US and Canada. In addition, Animas has selected Medtronic to be its partner-of-choice to support Animas customers through this time. Our top priority is to ensure that people using Animas pumps can stay on pump therapy and receive the supplies and support they need, while continuing to support our existing Medtronic customers. If you’re a Medtronic pumper, this does not impact you at all. You are, and always will be, invaluable members of our community. Whether you’ve been with us for 30 years or are a new addition to the family, we are inspired by you. You’re the reason we come to work every day excited to develop innovative products and services that help you live well and chase your dreams (whatever that may be). If you currently use an Animas insulin pump, I want to welcome you to the Medtronic family and assure you that we know the technology you use to manage your diabetes is an important, personal decision. We are here for you and committed to supporting you every step of the way. Nothing will change for you right away. However, here’s what this announcement means for you over the coming months: If your Animas pump is currently out of warranty, you can visit medtronicdiabetes.com/animas to explore your upgrade options. Please keep in mind that this arrangement does not impact Animas customers outside of the US or Canada at this time. It also does not impact those using OneTouch blood glucose meters. Again, please accept our warmest welcome to the Medtronic family. We’re honored to have the opportunity to extend to you the service and support that we Continue reading >>

J&j Closes Insulin Pump Business, Medtronic To Gain

J&j Closes Insulin Pump Business, Medtronic To Gain

Johnson & Johnson is closing its insulin pump business and the market may soon be down to two players. In early October, J&J announced it would shutter Animas Corp., its insulin delivery company subsidiary, and transition its approximately 90,000 existing customers to Medtronic plc, the primary player in the pump market. “With changing needs of customers, rapidly evolving market dynamics, and increased competitive pressures, it proved too difficult to sustain the insulin pump business and we decided to pursue an exit of the business,” Valerie Asbury, general manager of Animas, said in a statement. LEARN MORE BNA’s Health Care Daily Report™ sets the standard for reliable, timely coverage of breaking health care news, covering all major legal, policy, industry, and consumer developments in a rapidly changing landscape every business day. The consolidation will affect patient choice in the diabetes pump market and could mean tighter pump supplies because one of the remaining major pump manufacturing facilities is in Puerto Rico, which has been devastated by recent hurricanes. Before the Animas shutdown, J&J had 12 to 14 percent of the pump market, and Medtronic had about 70 percent, David Kliff, publisher of the Chicago-based Diabetic Investor, told Bloomberg Law Oct. 20. Post-shutdown, Medtronic will have closer to 85 percent of the market, he said. $3.5 Billion Market The total U.S. insulin pump market, including the pumps and their associated supplies, is worth about $3.5 billion annually, Kliff said. Animas’s closure leaves three insulin pump manufacturers still in the game: one is the market giant, Dublin, Ireland-based Medtronic; the other two are Billerica, Mass.-based Insulet Corp. and San Diego-based Tandem Diabetes Inc. Kliff expects further consolidati Continue reading >>

Animas® Vibe™ Insulin Pump & Cgm System, Pink

Animas® Vibe™ Insulin Pump & Cgm System, Pink

Each of 1 EA Item # AN11551400EP HCPCS Code: E0784 Manufacturer: ANIMAS CORPORATION Prescription required The Animas® Vibe™ Insulin Pump Adult indication and CGM System is approved for use by people age 18 and older. As an integrated system, Animas® Vibe™ allows patients to view glucose data and trends in color, as well as administer insulin directly from the Animas® pump, both of which simplify and aid in a patient’s ability to make more informed decisions and fine-tune insulin delivery. CGM-enabled systems, like Animas® Vibe™, provide patients with a more complete glucose picture compared to fingersticks alone. The system delivers real-time glucose information and alerts for high and low readings.(A glucose reading must be confirmed with a fingerstick test before taking action.) Fine-tuned insulin delivery: The Animas® Vibe™ is equipped with a Swiss-made motor and offers as low of a basal rate increment as 0.025U/hr (available ranges 0.025U/hr to 25U/hr) and a low bolus increment of 0.05U across all available bolus ranges (0.05U to 35U) to adjust and deliver precise increments of insulin to help the body’s changing needs. CGM in full color: The first and only CGM-enabled pump with a high-contrast color screen with color-coded trend arrows to show where glucose readings are heading and how fast, revealing the latest glucose values and trends at a glance. The smallest introducer needle: The Dexcom G4® Platinum Sensor is tiny, round and flexible with the smallest introducer needle available. An accurate, longest-wear sensor: With Mean ARD (Absolute Relative Difference) as the industry’s standard for measuring CGM accuracy, the Dexcom G4® Platinum sensor's 13% Mean ARD provides exceptional performance and accuracy for reliable results. Dexcom sensors Continue reading >>

Animas Insulin Pumps Are Being Discontinued And “users Must Be Supported”

Animas Insulin Pumps Are Being Discontinued And “users Must Be Supported”

Diabetes care company Animas is to close down. This means that in the long term, Animas Vibe insulin pumps will no longer be available. The sale of all Animas Vibe and OneTouch Ping insulin pumps has been discontinued with immediate effect in the US and Canada. For Europe and the UK this process, which will see Animas ceasing operation and sale of pumps, will take much longer. Johnson & Johnson, the firm behind Animas, said on 5 October 2017 that Animas pumps and products will continue to be available through healthcare providers and for sale as normal in the UK for an as yet unconfirmed but limited period of time. Johnson & Johnson will provide further information for UK Animas pump users, including what their options are for using different pumps, in due course. The firm has also said Animas will continue to provide customer service, training and warranty support, including providing pump supplies that are used with the Animas Vibe, during a limited ‘transition period’. The length of time this will be available has yet to be confirmed. Other Johnson & Johnson Diabetes Care companies, including blood glucose monitoring focused Lifescan, which includes OneTouch branded products, and Calibra, producers of an insulin patch pump, are not included in this change. Karen Addington, UK Chief Executive of JDRF said: “This news is concerning and JDRF is monitoring the situation. Users of these particular insulin pumps must not be negatively affected in any way. They should be supported by Animas and their healthcare team to move smoothly on to alternative pumps.” If you have any questions about how this might affect you please call Animas Patient Support on 0800 055 6606 in the UK or 1800 812 715 in Republic of Ireland. Continue reading >>

Johnson & Johnson's Animas To Shut Down Ops And Exit Insulin Pump Biz, 410 Jobs Affected

Johnson & Johnson's Animas To Shut Down Ops And Exit Insulin Pump Biz, 410 Jobs Affected

October 5, 2017 By Alex Keown, BioSpace.com Breaking News Staff CHESTERBROOK, Pa. – Animas Corporation, a Johnson & Johnson division focused on diabetes care, is exiting the space and shutting down operations and laying off 410 employees. This morning, Pennsylvania-based Animas Corporation will discontinue the manufacturing and sale of the insulin pumps it manufactures, Animas Vibe and One-Touch Ping. The two pumps are used by approximately 90,000 diabetes patients. In a statement issued this morning, Animas said patients using its products will be allowed to transition their needs to rival company Medtronic plc . Animas said it will continue to provide customer service, training and warranty support to insulin-pump customers through a transition period, although how long that period will be was not disclosed. Johnson & Johnson announced earlier this year that it was exploring strategic options to maximize shareholder value and one of those was the possible sale of its diabetes care business. In January, J&J said it planned to seek a possible sale, joint venture or operating partnerships for LifeScan Inc., Animas and Calibra Medical Inc.. as part of a plan to spark growth. This morning, Johnson & Johnson said it will continue to evaluate potential strategic options for LifeScan, Inc. and its blood glucose monitoring OneTouch brand of products. In its statement announcing the close of Animas, the company said the decision to shutter Animas was due to the changing needs of customers, market dynamics and increased competition. The combination of challenges made it “too difficult to sustain the insulin pump business” and the decision was made to close down Animas. Animas is moving quickly with its decision. As of today, the company has discontinued sales of its insuli Continue reading >>

Insulin Pumps...

Insulin Pumps...

This does not replace any medical advice. The following is for your information only. Please feel free to share with your diabetes team but it does not make any changes in your diabetes management without first consulting your diabetes team An insulin pump is not a cure but another method of insulin delivery. It is a small pager-like device that mechanically pumps set amounts of fast-acting insulin into the patient's body. This is not yet a closed loop system. It is a system that requires the setting of "basal rates" and the calculation of various insulin to food ratios to be used in the run of a day. Unlike Multiple Daily Injection therapy (MDI), pump therapy does not use a long-lasting insulin but small amounts of fast-acting insulin are delivered throughout the day. For some this leads to feelings of unease as the threat of DKA (Diabetic Ketoacidosis) looms greater. For others it simply leads to feelings of freedom as they no longer are forced to follow the clock. The peaks of long-lasting NPH insulins may have been a problem, or the single basal rate offered by insulin glargine may not match their body's needs. An insulin pump lets you set a variety of "basal rates" to meet the naturally occurring needs of your body. It further allows you to match insulin to carbohydrate intake rather than having to "feed" your insulin. You now chose to eat, snack or graze. Pumping insulin is not for everyone. It is another method of insulin delivery. Some do not like the idea of being attached to a mechanical device 24/7 but the freedom, flexibility and tight control often outweighs any of the negative concerns. Please take your time when choosing an insulin pump. You need to the pump to fit with your needs and your lifestyle. We have a detailed outline of each pump company's curre Continue reading >>

Animas To Discontinue Manufacturing And Sale Of Insulin Pumps

Animas To Discontinue Manufacturing And Sale Of Insulin Pumps

Animas Corporation has announced that it will discontinue the manufacturing and sale of Animas® Vibe® and OneTouch Ping® insulin pumps, close operations and exit the insulin pump business. Animas has selected Medtronic as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers. Patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump. Patient safety and continuity of care is of utmost importance and Animas will continue to provide customer service, training and warranty support, including providing pump supplies that are used in conjunction with the Animas® Vibe® and OneTouch Ping® insulin pumps, through a transition period. “We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure them that we will be with them every step of the way throughout this transition,” said Valerie Asbury, General Manager of Animas Corporation. “Our number one priority is ensuring patients have a seamless experience as they transition to Medtronic. For over 30 years, Medtronic has been a global leader in the treatment of those living with diabetes, and we are confident they will provide outstanding support to our patients and their healthcare teams.” “We are incredibly grateful to our patients and healthcare partners for the trust, confidence and loyalty they have placed in Animas products over the last 12 years,” Asbury said. “With changing needs of customers, rapidly evolving market dynamics, and increased competitive pressures, it proved too difficult to sustain the insulin pump business and we decided to pursue an exit of the business. This decision was extremely difficult and comes following the extensive exploration Continue reading >>

Breaking News In Diabetes – Animas Halts Insulin Pump Production

Breaking News In Diabetes – Animas Halts Insulin Pump Production

This past Thursday, October 5, 2017, the Diabetes community was rocked by the announcement that Animas Corporation will no longer be manufacturing its insulin pumps, the Animas Vibe and One Touch Ping. The companies decision affects more than 90,000 Animas pump users in the US and Canada. Sale of the pumps world-wide will continue for now. Continuous Glucose Monitoring (CGM) products manufactured by Animas will continue. Animas partners with Medtronics Animas will be partnering with Medtronics to switch patients to their pumps instead over a period of time. Animas is assuring patients that they will have the same service for their existing insulin pumps, but in some Type 1 communities, reports are being shared that people have already lost their insulin pump representatives. I advise reading the following pieces: What does the announcement mean for pumpers in the diabetes community? All over Facebook, the Type 1 community is worried, as corporate decisions affect patient decisions, and quality of life. If you go to the Animas website, you will see the announcement, along with important links about the transition, and phone numbers to call Medtronics to discuss your options. Will there be time before I have to switch my pump to Medtronics? Animas promises to continue warranty service and support, and to continue to provide all pump supplies needed through the transition. For warranties that go out after September 30, 2019, patients should receive a contact from Medtronics to transfer to their pump, the Medtronics 630G, at no additional cost. If you have a pump where the warranty expired earlier before September 30, 2019, then Animas says that you are still under their warranty through the transition, and will still have serviced. They say it’s business as usual, and to Continue reading >>

Here For You.

Here For You.

Animas recently announced it has discontinued sales of its pumps in the United States and Canada and will close its pump business. As Animas’ partner-of-choice for this transition, our Medtronic team is ready to help. We know that when it comes to your diabetes management needs, it’s a very personal decision and our experienced team is here to support you through every step in the process. Over the past 30 years, we have set out to transform diabetes care to enable greater freedom and better health through innovations across the care continuum, through advanced pump and CGM therapies, and comprehensive services like our StartRight Program and 24-hour Helpline that has served over 1.2 million people in more than 100 countries worldwide to date. In fact, our unparalleled service is the #1 reason our customers stay with us. Guided by our Medtronic Mission, we continually strive to address unmet needs through best-in-class solutions for people with diabetes around the world. Stay Connected We make it easy for our customers to stay connected with us and others in the Diabetes Online Community. Through our social channels, we share helpful diabetes tips, stories and perspectives from the community as well as from our Medtronic team. We count on our robust online community to give us feedback and help shape the solutions we innovate to help transform diabetes care so we invite you to join the conversation and stay connected with us! If you need pump supplies or customer support for your current Animas pump, you can continue to use the same methods you do today – nothing changes for now. As always, an Animas team member can be reached at 877-937-7867 (US) and 866-406-4844 (Canada). If your pump warranty has expired, you’re at risk of going off therapy should something h Continue reading >>

After Ceasing Animas Insulin Pump Sales In U.s., Canada, J&j To Lay Off 297

After Ceasing Animas Insulin Pump Sales In U.s., Canada, J&j To Lay Off 297

Earlier this month, Johnson & Johnson announced it would stop manufacturing and selling its Animas insulin pumps in the U.S. and Canada, effective immediately. Now, a WARN notice shows, the company will lay off 297 employees in Pennsylvania. The layoffs, effective Dec. 15, will affect employees at Johnson & Johnson sites in West Chester and Wayne, according to the Pennsylvania WARN notice. Animas employs about 410 people globally, about half of whom work at its Chesterbrook site in Wayne and a manufacturing facility in West Chester, according to The Philadelphia Inquirer. The Chesterbrook site also houses J&J’s LifeScan unit and its Diabetes Institute. "Animas has discontinued the sale of all Animas Vibe and OneTouch Ping insulin pumps in the U.S. and Canada, effective immediately. A decision and timing to exit countries outside of the U.S. and Canada is subject to completing consultation with relevant works councils. For the patients, caregivers and healthcare providers outside of the U.S. and Canada who currently use Animas pumps and products, Animas will continue to sell pumps and operate as usual," said Bridget Kimmel, a J&J spokeswoman, in an email. The company partnered with Medtronic to offer Animas pump users the opportunity to transfer to a new device. Soon after J&J’s announcement, Insulet offered a free trial of its tubeless, “pod-based” insulin pump to Animas users. And this week, Insulet teamed up with Dexcom to provide its Omnipod system along with a $200 gift card toward Dexcom’s G5 Mobile continuous glucose monitor. RELATED: J&J alerts patients to insulin pump cybersecurity flaws, but says risk is low J&J acquired Animas in 2005 for $518 million. The insulin pump business along with LifeScan, which makes blood glucose monitors, and Calibra Medi Continue reading >>

Animas Shutting Down: What You Need To Know

Animas Shutting Down: What You Need To Know

Animas announced on October 5, 2017 that it is exiting the insulin pump business immediately and will no longer make and sell it’s Animas Vibe and OneTouch Ping insulin pumps. For current users, Animas will continue to have customer service for existing users of their pumps and provide warranty support. They will honor warranties and will continue providing the supplies used with their pumps. Who Is Affected? Current Animas customers in the US and Canada are affected by this announcement. Nothing is changing for patients using Animas pumps in other parts of the world (i.e., outside of the US and Canada). What If I Have an Animas Pump and I’m Under Warranty? If you are on a pump with a warranty that expires on or after September 30, 2019, you or your pump supplier will be contacted by a member of the Medtronic transition team concerning the option to transfer to a Medtronic 630G insulin delivery system at no cost. If your warranty expires before September 30, 2019, Animas will continue to honor your warranty until your warranty expires and you transition to a new pump. What If I Have an Animas Pump and I’m Not Under Warranty? If your pump is not under warranty or your pump has a warranty expiring by December 31, 2017, you may explore your options as you normally would by consulting with your diabetes care team and insurance company to select a new insulin pump, if needed. Can I Still Order Animas Supplies? Yes, Animas will continue to provide supplies to Animas pump users. What Other Insulin Pumps Are Available? Animas is partnering with Medtronic to transition patients (medtronicdiabetes.com/Animas). Though, please note that people with diabetes should consult with their medical team to make decisions about what insulin pump to transition to. You shouldn’t be fo Continue reading >>

Animas Closes Operations And Exits Insulin Pump Market

Animas Closes Operations And Exits Insulin Pump Market

By Adam Brown and Kelly Close What are the options for approximately 90,000 Animas pumpers worldwide and for others considering a new pump? What does it mean for the pump market and patient choice? On October 5, Johnson & Johnson (J&J) announced in disappointing news that Animas is closing operations and exiting the insulin pump market, affecting approximately 90,000 Animas pumpers worldwide. Click to Jump to FAQs: My warranty hasn’t expired yet. What can I do? My Animas pump warranty expires after September 30, 2019 (i.e., pump is 0-2 years old). What can I do? What pumps are currently available in the US? What is coming soon, especially with automated insulin delivery? Effective immediately in the US and Canada, Animas will no longer manufacture and sell the Vibe and OneTouch Ping insulin pumps, and will continue to offer supplies, customer service, training, and warranty support through a transition period. “Partner-of-choice” Medtronic will take over Animas supply reordering and support in the “next few months.” The companies will send an email with more details soon. We’d assume Animas’ exit is also coming very soon in other countries besides the US and Canada. For now, Animas pumpers can stay on their Animas pumps and continue to access supplies, and will need to decide what pump to move to next – see below for the different options between Medtronic, Insulet, and Tandem in the US, depending on preferences and warranty timing. For those who acquired an Animas pump in the last two years, a free upgrade is only available to Medtronic's less advanced MiniMed 630G pump. Read an open letter from The diaTribe Foundation about this decision here. Although the closing of the business is not unexpected – J&J has been considering a sale or partnership of t Continue reading >>

More in diabetes